Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 10/20 | 0.49 |
| ▸ | F2 | P00734 | 9/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788299 | 0.94 | PSMB5 (0.50) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL2786821 | 0.94 | PSMB5 (0.55) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL2786801 | 0.92 | PSMB5 (0.49) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL2873772 | 0.92 | PSMB5 (0.51) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL2791337 | 0.92 | F2 (0.51) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL2790264 | 0.91 | PSMB5 (0.50) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL15862049 | 0.91 | F2 (0.57) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL2876319 | 0.91 | PSMB5 (0.49) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL2876320 | 0.90 | PSMB5 (0.49) | PSMB5F2PRSS1PSEN1PSEN2 | |
| SCHEMBL17337287 | 0.89 | PSMB5 (0.54) | PSMB5F2PRSS1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL, LTD. (BM) | 2010-11-11 | — | — | US | disclosed |
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | PROTEZ PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120715-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PSMB5 1165/4885F2 2849/4885PRSS1 1459/4885 |
| US-20100286092-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | PSMB5 1165/4885F2 2849/4885PRSS1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.